A 3-Tier, Immunophenotype-Guided Approach to Overlapping AD and Alopecia Areata

Patients with moderate to severe or very severe alopecia areata have a 3.2% to 17.4% chance of also living with atopic dermatitis, and treating one disease can unpredictably reshape the course of the other.

How Often Atopic Dermatitis and Alopecia Areata Coexist

Atopic dermatitis (AD) and alopecia areata (AA) are chronic immune-mediated diseases that often occur together in the same patient, according to a review published in the Journal of Clinical and Aesthetic Dermatology.¹ The overlap compounds disease burden and psychosocial harm, driving growing off-label use of AD biologics and Janus kinase (JAK) inhibitors meant to treat both conditions, the authors wrote.

The stakes extend beyond dermatology. A separate review in Clinical and Translational Allergy found that AD raises AA risk roughly 26-fold compared with healthy controls, with up to 16% of adults with AD also affected.² Both diseases carry substantial out-of-pocket costs, lost productivity, and impaired quality of life, adding urgency to calls for biomarker-informed treatment rather than trial-and-error prescribing.

Mapping Immune Pathways Instead of Summarizing Single Agents

Rather than cataloging efficacy data for individual drugs, the review integrated immunophenotyping data across AD and AA into a practical, endotype-based framework for selecting and sequencing systemic therapy, drawing on case reports, case series, trial extension data, network meta-analyses, and genome-wide association studies.

AD is classically driven by T-helper cell type 2 (TH2) and TH22 cytokine signatures, including interleukin (IL)-4, IL-13, and IL-31, while AA has traditionally been framed as a TH1 and interferon (IFN)-γ-mediated autoimmune attack on hair follicle immune privilege. The review found meaningful overlap between the 2: AA also shows TH2 and TH17/TH22 involvement in some patients, particularly those with concomitant atopic disease or high immunoglobulin E (IgE), and both diseases converge on shared JAK-signal transducer and activator of transcription (STAT) signaling and the OX40/OX40L costimulatory pathway.

Dupilumab, JAK Inhibitors, and Divergent Effects on Hair

Biologics such as dupilumab, tralokinumab, and lebrikizumab reliably control AD, and some TH2-high, high-IgE patients gain hair regrowth alongside skin clearance, the review noted. However, new-onset or worsening AA has also been reported with these agents, suggesting TH2 blockade alone can sometimes unmask disease rather than resolve it.

JAK inhibitors, particularly the JAK1-biased agents abrocitinib and upadacitinib, showed a more consistent dual benefit, with reviews finding significant scalp, eyebrow, and eyelash regrowth in AA across disease severities alongside rapid improvement in eczema and itch. “JAK inhibitors provide the advantage of achieving the most consistent dual control of AD and AA, accompanied by the need to perform baseline and periodic clinical and laboratory monitoring due to potential adverse effects,” the authors wrote, citing routine blood counts, metabolic panels, and thromboembolism risk checks as the tradeoff.

A 3-Tier Approach to Selecting and Switching Therapy

The authors proposed sorting patients into 3 immunophenotype archetypes: a TH2-high AD/AA group marked by early-onset AD, strong atopic history, and elevated IgE and eosinophils; a TH1/IFN-γ-high, AA-dominant group with severe, often nonatopic hair loss and low or normal IgE; and a mixed or “switching” archetype whose disease drifts between the 2 patterns over time. Initial therapy would follow the dominant archetype, favoring an IL-4/IL-13-targeting biologic in TH2-high disease or a JAK1-biased inhibitor in TH1-dominant disease, with explicit triggers for adding or switching agents if outcomes fail to improve within 6 to 9 months.

The framework leans on low-burden monitoring: the 6-item Atopic Dermatitis Control Tool, completed in the waiting room, with a score of 7 or higher signaling poor control and a change of 5 points or more marking meaningful change, paired with standardized scalp photographs taken from 4 to 5 angles per visit. Consistency in whichever method a practice chooses matters more than which tool is used, the authors emphasized.

Case-Report Evidence and Coverage Barriers Complicate Use

The authors acknowledged the evidence underlying this framework remains thin: current data are dominated by short- to medium-term trials designed for regulatory approval and by heterogeneous case reports, with few prospective studies built specifically around comorbid AD and AA. Large, multicenter registries linking phenotype, biomarkers, and treatment sequencing were identified as a priority to validate the proposed archetypes.

Real-world access adds another layer of difficulty, a point especially relevant to payers and health system administrators. Survey data cited in the review found nearly half of patients with AD experienced at least 1 insurance-related delay or denial in the prior year, with prior authorization responsible for 55% of those delays, and off-label JAK inhibitor requests for AA were frequently denied on first submission, often under a “cosmetic” classification. For clinicians managing both diseases, immunophenotype-guided prescribing is scientifically ready before it is administratively easy, the authors concluded, making standardized biomarker panels and clearer coverage pathways the next practical steps.

References

1. Deriss M, Del Rosso JQ, Mesinkovska N. The concurrence of atopic dermatitis and alopecia areata: how common is it? Why does it happen? How is this managed optimally in clinical practice? J Clin Aesthet Dermatol. 2026;19(5):28-34.
2. Stevanovic K, Pereira M, Nguyen O, van Hofman I, Meesch C, Zuberbier T. 20 years of the socioeconomic impact of atopic dermatitis and alopecia areata from around the globe. Clin Transl Allergy. 2025;15(5):e70061. doi:10.1002/clt2.70061